Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
Primary Purpose
Meconium Ileus, Very Low Birth Weight Infant
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Gastrografin
Sterile water
Sponsored by
About this trial
This is an interventional treatment trial for Meconium Ileus focused on measuring VLBW infant, Meconium, Enteral nutrition, Meconium passage
Eligibility Criteria
Inclusion Criteria:
- premature infants with a birthweight < 1500g and a gestational age < 32 weeks
Exclusion Criteria:
- major congenital disorders
- chromosomal aberrations
- systemic metabolic disease and
- pre-existing gastrointestinal abnormalities (i.e. Morbus Hirschsprung)
- pre-existing conditions of severe hypotension
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Gastrografin
Sterile water
Arm Description
infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
infants receive 9ml/kg sterile water
Outcomes
Primary Outcome Measures
Time to Complete Meconium Evacuation in Days
Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life
Secondary Outcome Measures
Feeding Tolerance- Full Enteral Feedings
full enteral feeding is defined in days of life from birth until an an infant tolerates an enteral feeding volume of 140ml/kg
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01515696
Brief Title
Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
Official Title
Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants- a Phase 4 Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
February 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Nadja Haiden,MD
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population.
Detailed Description
In premature infants the establishment of proper gastrointestinal function is challenging and often associated with delayed meconium passage. Meconium evacuation depends on gestational age and birthweight: the more immature an infant is, the later meconium passage starts and the longer meconium passage lasts. The mean duration of meconium evacuation in premature infants with a gestational age below 30 weeks is 8 days, while mature infants excrete their meconium in 2 days. The obstruction of deep intestinal segments by tenacious, sticky meconium frequently leads to gastric residuals, a distended abdomen and delayed food passage. The time lag to full enteral feedings is extended, the probability to acquire infections due to intravenous access for parenteral nutrition increases and the hospital stay of the infant is prolonged. However, the relation between meconium passage and feeding tolerance remains controversial. While one study showed that there is little concordance between first meconium passage and feeding tolerance, an other one showed that rapid and complete excretion of meconium is crucial for oral feeding tolerance and has a positive effect on it. Recently, the investigators performed a prospective randomized trial to determine, whether repeated prophylactic applications of small volume glycerin enemas accelerate passage of meconium in very low birth weight (VLBW) infants. Disappointingly, application of enemas did not accelerate meconium evacuation. A possible reason for the ineffectiveness of glycerin enemas is that the volume used was too small to mobilize tenacious meconium sufficiently from the colon and small bowel.
Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be more effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized, that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population. The objective of the present study is to determine whether the enteral application of the osmotic contrast agent Gastrografin® accelerates complete meconium excretion and improves feeding tolerance in very low birth weight infants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meconium Ileus, Very Low Birth Weight Infant
Keywords
VLBW infant, Meconium, Enteral nutrition, Meconium passage
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
96 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Gastrografin
Arm Type
Active Comparator
Arm Description
infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
Arm Title
Sterile water
Arm Type
Placebo Comparator
Arm Description
infants receive 9ml/kg sterile water
Intervention Type
Drug
Intervention Name(s)
Gastrografin
Other Intervention Name(s)
Diatrizoate Meglumine, Diatrizoate Sodium, NDA-011245
Intervention Description
Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
Intervention Type
Drug
Intervention Name(s)
Sterile water
Other Intervention Name(s)
Sterile water (ANDA) #077393
Intervention Description
Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
Primary Outcome Measure Information:
Title
Time to Complete Meconium Evacuation in Days
Description
Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life
Time Frame
days of life until until the complete meconium evacuation from birth up to 40 days of life
Secondary Outcome Measure Information:
Title
Feeding Tolerance- Full Enteral Feedings
Description
full enteral feeding is defined in days of life from birth until an an infant tolerates an enteral feeding volume of 140ml/kg
Time Frame
days of life from birth until an infant tolerates en enteral feeding volume of 140 ml/kg
10. Eligibility
Sex
All
Maximum Age & Unit of Time
24 Hours
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
premature infants with a birthweight < 1500g and a gestational age < 32 weeks
Exclusion Criteria:
major congenital disorders
chromosomal aberrations
systemic metabolic disease and
pre-existing gastrointestinal abnormalities (i.e. Morbus Hirschsprung)
pre-existing conditions of severe hypotension
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nadja Haiden, MD
Organizational Affiliation
Medical university of Vienna, Department of Pediatrics
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
We'll reach out to this number within 24 hrs